VCA Stocks

Vaccinex Inc., a Rochester, N.Y.-based developer of antibodies, has raised $25 million in Series B-2 funding.  Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies to treat a variety of serious diseases.  The company’s current antibody drug development efforts are focused on cancer, autoimmune and inflammatory diseases.